Charles L. Spurr Professor of Medicine; Director, Comprehensive Cancer Center; Chair, Department of Cancer Biology
Oncology
Dr. Boris Pasche, MD
|
|
Give Review
Boris Pasche works in the field of Oncology. He over the years received 5 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Meaningful Use Stage 1 Certification", "Elected Member" and "Whos Who in Medicine and Healthcare". Boris Pasche, MD is a published MD. He has 66 publications published. The most current publication "Molecular analysis of SALL1 mutations in Townes-Brocks syndrome."
Publications
- Non-small cell lung Cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design.
- Targeted treatment of Cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies.
- Selecting patients for cytotoxic therapies in gastroenteropancreatic Neuroendocrine tumours.
- Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.
- Molecular Analysis of SALL1 mutations in Townes-Brocks syndrome.
- Impairment of gastric acid secretion and increase of embryonic lethality in Foxq1-deficient mice.
- Bright light and LEET effects on circadian rhythms, sleep and cognitive performance.
- MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells.
- Effects of low energy emission therapy in chronic psychophysiological insomnia.
- Cancer cell proliferation is inhibited by specific modulation frequencies.
- Sleep inducing effect of low energy emission therapy.
- Electroencephalographic changes following low energy emission therapy.
- TGFBR1*6A is not associated with prostate Cancer in men of European ancestry.
- Role of transforming growth factor beta in Cancer.
- Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields.
- TbetaR-I(6A) is a candidate tumor susceptibility allele.
- Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine Tract.
- Age at first birth and the risk of breast Cancer in BRCA1 and BRCA2 mutation carriers.
- Whole-genome sequencing: a step closer to personalized medicine.
- The role of the fat mass and obesity associated gene (FTO) in breast Cancer risk.
- TGFBR1 signaling and breast Cancer.
- Polymorphisms of ADIPOQ and ADIPOR1 and prostate Cancer risk.
- Bayesian Analysis of genetic interactions in case-control studies, with application to adiponectin genes and colorectal cancer risk.
- Cancer genetics. Introduction.
- Tgf-beta signaling alterations and colon Cancer.
- Constitutively decreased TGFBR1 allelic expression is a common finding in coloRectal cancer and is associated with three TGFBR1 SNPs.
- Candidate gene association studies: successes and failures.
- Caring for patients with Cancer.
- The cover. Physichromie no. 965.
- Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic preCancer.
- TGFBR1 haplotypes and risk of non-small-cell lung Cancer.
- One step forward toward identification of the genetic signature of glioblastomas.
- Amplitude-modulated electromagnetic fields for the treatment of Cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach.
- Transforming growth factor beta as a therapeutic target in systemic sclerosis.
- Tgfbr1 haploinsufficiency is a potent modifier of coloRectal cancer development.
- Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis.
- Role of polymorphisms in Adamantiades-Behçet's disease.
- Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and coloRectal cancer risk.
- Germline allele-specific expression of TGFBR1 confers an increased risk of coloRectal cancer.
- No association of TGFB1 L10P genotypes and breast Cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.
- Familial coloRectal cancer: a genetics treasure trove for medical discovery.
- Variants of the adiponectin and adiponectin receptor 1 genes and breast Cancer risk.
- Genetics and genomics for clinicians.
- TGFBR1*6A enhances the migration and invasion of MCF-7 breast Cancer cells through RhoA activation.
- Recent advances in breast Cancer genetics.
- Targeting transforming growth factor-beta signaling.
- Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon Cancer development.
- Genetics and genomics: a call for papers.
- New insights into breast Cancer genetics and impact on patient management.
- TGF-beta signaling alterations and susceptibility to coloRectal cancer.
- A new strategy in the war on renal cell Cancer: hitting multiple targets with limited collateral damage.
- ColoRectal Cancer Screening Clinical Practice Guidelines.
- Genetic/familial high-risk assessment: Breast and ovarian.
- Transforming Growth Factor Beta and breast Cancer.
- Somatic acquisition and signaling of TGFBR1*6A in Cancer.
- TGFBR1*6A may contribute to hereditary coloRectal cancer.
- Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast Cancer risk.
- No major association between TGFBR1*6A and prostate Cancer.
- Role of TGF-beta in Cancer and the potential for therapy and prevention.
- Targeting non-small cell lung Cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
- TGFBR1*6A and cancer: a meta-Analysis of 12 case-control studies.
- Is C-reactive protein an inflammation opsonin that signals colon Cancer risk?
- TGFBR1*6A and cancer risk: a meta-Analysis of seven case-control studies.
- TGF-beta signaling alterations in Cancer.
- Molecular markers in prognosis of coloRectal cancer and prediction of response to treatment.
Schools
Karolinska Institutet Medicinska Fakulteten
Ny Hospcornell Med Center
Meml Sloan Kettering Cancer Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Meaningful Use Stage 1 Certification
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
Memorial Sloan-Kettering Cancer Center -
New York Presbyterian Hospital - Cornell Campus -
Karolinska Institute Faculty of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Susan H. McDunn, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shira N. Dinner, MD |
|
|
Dr. Victoria M. Villaflor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey C. Cilley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven B. Newman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Walter M. Stadler, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Paramjeet G. Khosla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrzej J. Jakubowiak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip Bonomi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Don V. Hellerman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin C. Conlon, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Syed S. Hassan, MD |
|
|
Dr. Gladell Paner, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Stanley G. Schade Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raymond C. Bergan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher A. Sequeira, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Sangeeta R. Mehendale, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randy F. Sweis, MD
This Doctor is OpenDoctor Recommended.
|